申萬宏源(06806.HK)完成發行10億元公司債
格隆匯5月14日丨申萬宏源(06806.HK)公告,根據中國證券監督管理委員會《關於同意申萬宏源證券有限公司向專業投資者公開發行公司債券註冊的批覆》(證監許可(2024)57號),公司所屬申萬宏源證券有限公司獲準向專業投資者公開發行面值總額不超過人民幣200億元公司債券。
2025年5月13日,申萬宏源證券有限公司2025年面向專業投資者公開發行科技創新公司債券(第一期)(以下簡稱“本期債券”完成發行工作。本期債券發行規模人民幣10億元,期限3年,票面利率1.69%。本期債券登記完成後擬於深圳證券交易所上市交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.